Physician profile
Jenny Lin
NPI 1013145515
$3,856.50
in general payments reported to CMS, 2019-2025
22 companies · $465 in 2025
The $465 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $188 · 2022: $621 · 2023: $531 · 2024: $99.39 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.48 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $706.93 | 2019-2025 | |
| Amgen INC. | $400.90 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $332.03 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $258.00 | 2019-2025 | |
| Janssen Biotech, INC. | $213.30 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Medexus Pharma, INC. | $205.33 | 2019 | |
| Atricure, INC. | $175.71 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.96 | 2019-2023 | Ofev |
| Lilly USA, LLC | $138.78 | 2019-2022 | |
| Celgene Corporation | $91.74 | 2019 | |
| Horizon Therapeutics Plc | $87.47 | 2019-2022 | |
| Genzyme Corporation | $53.85 | 2022-2025 | |
| Glaxosmithkline, LLC. | $35.42 | 2019 | |
| Janssen Scientific Affairs, LLC | $30.28 | 2024 | Tremfya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $22.06 | 2023 | Hulio |
| Csl Behring | $20.60 | 2023 | Hizentra |
| Hikma Pharmaceuticals USA | $19.90 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.53 | 2023 | Lupkynis |
| Astrazeneca Pharmaceuticals Lp | $15.87 | 2022 | |
| Genentech USA, INC. | $14.25 | 2019 | |
| Merck Sharp & Dohme LLC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.